MedCity News January 25, 2022
Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.
Fresh off a licensing deal that gives Leyden Labs a key building block for a medication that provides broad protection against influenza, the biotech unveiled $140 million to advance that product candidate and others in development as nasal spray formulations intended to stop respiratory pathogens at their point of entry.
Casdin Capital and GV, both of which previously invested in the biotech, led the Series B financing. The announcement of the new capital Tuesday comes one...
Today's Sponsors
Today's Sponsor